title: Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.
authors.affiliation: Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
authors.forename: Julie R
authors.initials: JR
authors.lastname: McMullen
authors.affiliation: Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
authors.forename: Esther J H
authors.initials: EJ
authors.lastname: Boey
authors.affiliation: Baker IDI Heart and Diabetes Institute, Melbourne, VIC, Australia.
authors.forename: Jenny Y Y
authors.initials: JY
authors.lastname: Ooi
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
authors.forename: John F
authors.initials: JF
authors.lastname: Seymour
authors.affiliation: Leukemia Department, University of Texas MD Anderson Cancer Center, Houston, TX.
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Keating
authors.affiliation: Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia Department of Medicine, University of Melbourne, Melbourne, VIC, Australia.
authors.forename: Constantine S
authors.initials: CS
authors.lastname: Tam
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D000831:Animals, Newborn; D001281:Atrial Fibrillation / Q000139:chemically induced / Q000378:metabolism*; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D006801:Humans; D007231:Infant, Newborn; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism*; D010880:Piperidines; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism*; D011720:Pyrazoles / Q000009:adverse effects* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D051381:Rats; D012307:Risk Factors; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D000225:Adenine; D000077329:Agammaglobulinaemia Tyrosine Kinase; D019869:Phosphatidylinositol 3-Kinases; D010880:Piperidines; D011505:Protein-Tyrosine Kinases; D051057:Proto-Oncogene Proteins c-akt; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib